WNK3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Adavosertib (SCHEMBL1504444)	1.00	1/20
SCHEMBL3454160	1.00	1/20
Adavosertib (SCHEMBL1504996)	0.98	1/20
Adavosertib (SCHEMBL1504998)	0.98	1/20
SCHEMBL1815951	0.94	1/20
Adavosertib (SCHEMBL3579242)	0.94	1/20
SCHEMBL6531688	0.93	1/20
SCHEMBL1811019	0.89	1/20
SCHEMBL1813967	0.89	1/20
SCHEMBL1813347	0.88	1/20
SCHEMBL1816446	0.88	1/20
SCHEMBL1813878	0.86	1/20
SCHEMBL1812482	0.85	1/20
SCHEMBL1812817	0.85	1/20
SCHEMBL1814334	0.85	1/20
SCHEMBL1812460	0.85	1/20
SCHEMBL1816265	0.85	1/20
SCHEMBL1811793	0.84	1/20
SCHEMBL3454514	0.83	1/20
SCHEMBL3454667	0.83	1/20

Clinical trials — most relevant to WNK3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Salt Loading and Thiazide Intervention Study	PHASE4	COMPLETED
Kallikrein-kinin (KKS) and Renin-angiotensin-aldosterone System (RAAS) in Primary Aldosteronism	PHASE4	COMPLETED
The Role of Mineralocorticoid Receptors in Vascular Function	PHASE2/PHASE3	COMPLETED
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
Selective Treatment According to Molecular Subtype of Prostate Cancer	PHASE2	UNKNOWN
Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?	PHASE2	COMPLETED
Antihypertensive Effect of Rostafuroxin Compared With Losartan in Hypertensive Patients Bearing Specified Gene Mutations	PHASE2	UNKNOWN
Effect of Gene Variants on Dopamine Receptor Natriuretic Responses	PHASE1	UNKNOWN
Mechanism and Effects of Manipulating Chloride Homeostasis in Acute Heart Failure	EARLY_PHASE1	COMPLETED
Effects of Different Forms of a Natural Heart Hormone on Blood Pressure and Fluid Balance in Healthy Volunteers	EARLY_PHASE1	COMPLETED
POTASSIUM-RICH SALT SUBSTITUTES IN KIDNEY TRANSPLANT RECIPIENTS	nan	NOT_YET_RECRUITING
Urinary Kallikrein and Hypertension: A Prospective Study	nan	COMPLETED
Defining the Brain Phenotype of Children With Williams Syndrome	nan	RECRUITING
HYPGENE-Genetics Fitness Obesity & Risk of Hypertension	nan	COMPLETED
From Micro- to Macro-vessels : Water, Salt, Heart and Kidneys	nan	COMPLETED
Establishment of Aldosterone and Renin Reference Range	nan	UNKNOWN
Study of Metabolic Modifications in Children With Noonan Syndrome	nan	COMPLETED
Transauricular Vagus Nerve Stimulation for Chronic Whiplash Associated Disorders	nan	RECRUITING
Podocyts Integrity in Glomerular Diseases	nan	UNKNOWN
Correlation Between Serum Chloride and Anion Gap Levels in DKA Patients	nan	UNKNOWN
Syndromes With Neonatal Salt Loss: Not Only Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency (21OH-ISC)	nan	RECRUITING
Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists.	nan	RECRUITING
An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in Indian People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Practice	nan	ACTIVE_NOT_RECRUITING
SEMASEARCH, Retrospective/Prospective Cohort Nested at ATUc/AP2 WEGOVY®	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Characterization of WAGR Syndrome and Other Chromosome 11 Gene Deletions	nan	COMPLETED
Genetic Analyses of Nonsyndromic and Syndromic Deafness in Pakistan	nan	ENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a WNK3 binder may also engage these)

Protein	Name	Similarity
Q80XP9	—	1.000	Q80XP9 →
Q9Z1J2	—	0.996	Q9Z1J2 →
P46200	—	0.996	P46200 →
Q811D2	—	0.996	Q811D2 →
Q9NYI0	—	0.996	Q9NYI0 →
Q90ZS6	—	0.995	Q90ZS6 →
BMP2K	BMP-2-inducible protein kinase	0.995	landscape →
F1MJR8	—	0.995	F1MJR8 →
F1M5M3	—	0.995	F1M5M3 →
Q5DW34	—	0.995	Q5DW34 →
A6QP06	—	0.995	A6QP06 →
P10244	—	0.994	P10244 →
Q6KAQ7	—	0.994	Q6KAQ7 →
Q71RC2	—	0.994	Q71RC2 →
Q6DFV7	—	0.994	Q6DFV7 →
O43310	—	0.994	O43310 →
A2ARZ3	—	0.994	A2ARZ3 →
Q2PFD7	—	0.994	Q2PFD7 →
Q6DFV3	—	0.993	Q6DFV3 →
Q9UHV7	—	0.993	Q9UHV7 →
Q8R4I4	—	0.993	Q8R4I4 →
Q2YDH8	—	0.993	Q2YDH8 →
Q8C0P0	—	0.993	Q8C0P0 →
MAP3K13	Mitogen-activated protein kinase kinase kinase 13	0.993	landscape →
Q949U2	—	0.993	Q949U2 →
Q8N573	—	0.993	Q8N573 →
P51954	—	0.993	P51954 →
Q3YC04	—	0.993	Q3YC04 →
Q2KHR2	—	0.993	Q2KHR2 →
Q9Z2U2	—	0.993	Q9Z2U2 →